November 9, 2023 Strong Top-line Performance and Strategic Progress in Q3 2023 • Q3 2023 SUBLOCADE® Net Revenue (NR) of $167m, +55% versus Q3 2022 • FY 2023 SUBLOCADE NR now expected to be $610m to $630m (vs. $590m to $630m) • OPVEE® launched; U.S. Biomedical Advanced Research and Development Authority (BARDA) contract secured | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------|------------|------------|----------|-------------|-------------|------------| | Period to Se ...